TY - JOUR
T1 - Antimicrobial use in European acute care hospitals: results from the second point prevalence survey (PPS) of healthcare-associated infections and antimicrobial use, 2016 to 2017
AU - Plachouras, Diamantis
AU - Kärki, Tommi
AU - Hansen, Sonja
AU - Hopkins, Susan
AU - Lyytikainen, Outi
AU - Moro, Maria Luisa
AU - Reilly, Jacqui
AU - Zarb, Peter
AU - Zingg, Walter
AU - Kinross, Pete
AU - Weist, Klaus
AU - Monnet, Dominique L.
AU - Suetens, Carl
AU - The Point Prevalence Survey Study Group
N1 - Acceptance in SAN > acceptance updated to match VoR EKT 07.05.20
AAM doesn't acknowledge GCU: this will be corrected in published version. 14/11/18 DC
VoR replaced AAM (OA)
Note duplicate record created (T. Hendry) and deleted. ET 2/5/19
PY - 2018/11/15
Y1 - 2018/11/15
N2 - Antimicrobial agents used to treat infections are lifesaving. Overuse may result in more frequent adverse effects and emergence of multidrug-resistant microorganisms. In 2016–17, we performed the second point-prevalence survey (PPS) of healthcare-associated infections (HAIs) and antimicrobial use in European acute care hospitals. We included 1,209 hospitals and 310,755 patients in 28 of 31 European Union/European Economic Area (EU/EEA) countries. The weighted prevalence of antimicrobial use in the EU/EEA was 30.5% (95% CI: 29.2–31.9%). The most common indication for prescribing antimicrobials was treatment of a commu-nity-acquired infection, followed by treatment of HAI and surgical prophylaxis. Over half (54.2%) of antimicrobials for surgical prophylaxis were prescribed for more than 1 day. The most common infections treated by antimicrobials were respiratory tract infections and the most commonly prescribed antimicrobial agents were penicillins with beta-lactamase inhibitors. There was wide variation of patients on antimicrobials, in the selection of antimicrobial agents and in antimicrobial stewardship resources and activities across the participating countries. The results of the PPS provide detailed information on antimicrobial use in European acute care hospitals, enable comparisons between countries and hospitals, and highlight key areas for national and European action that will support efforts towards prudent use of antimicrobials.
AB - Antimicrobial agents used to treat infections are lifesaving. Overuse may result in more frequent adverse effects and emergence of multidrug-resistant microorganisms. In 2016–17, we performed the second point-prevalence survey (PPS) of healthcare-associated infections (HAIs) and antimicrobial use in European acute care hospitals. We included 1,209 hospitals and 310,755 patients in 28 of 31 European Union/European Economic Area (EU/EEA) countries. The weighted prevalence of antimicrobial use in the EU/EEA was 30.5% (95% CI: 29.2–31.9%). The most common indication for prescribing antimicrobials was treatment of a commu-nity-acquired infection, followed by treatment of HAI and surgical prophylaxis. Over half (54.2%) of antimicrobials for surgical prophylaxis were prescribed for more than 1 day. The most common infections treated by antimicrobials were respiratory tract infections and the most commonly prescribed antimicrobial agents were penicillins with beta-lactamase inhibitors. There was wide variation of patients on antimicrobials, in the selection of antimicrobial agents and in antimicrobial stewardship resources and activities across the participating countries. The results of the PPS provide detailed information on antimicrobial use in European acute care hospitals, enable comparisons between countries and hospitals, and highlight key areas for national and European action that will support efforts towards prudent use of antimicrobials.
KW - Anti-Infective Agents/therapeutic use
KW - Community-Acquired Infections/drug therapy
KW - Cross Infection/drug therapy
KW - Drug Prescriptions/statistics & numerical data
KW - Drug Utilization/statistics & numerical data
KW - Female
KW - Hospitals/statistics & numerical data
KW - Humans
KW - Intensive Care Units
KW - Male
KW - Penicillins/therapeutic use
KW - Respiratory Tract Infections/drug therapy
KW - Surveys and Questionnaires
KW - beta-Lactamase Inhibitors/therapeutic use
U2 - 10.2807/1560-7917.ES.23.46.1800393
DO - 10.2807/1560-7917.ES.23.46.1800393
M3 - Article
C2 - 30458917
VL - 23
JO - Eurosurveillance
JF - Eurosurveillance
SN - 1560-7917
IS - 46
M1 - 1800393
ER -